Journal of Molecular Oncology Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Short Communication - Journal of Molecular Oncology Research (2023) Volume 7, Issue 5

Making Individualized Treatment Plans for Multi-Drug Chemotherapy

Kiyoto Mori *

Biomedical Engineering for Cancer, Ohoku University, Sendai, Japan

*Corresponding Author:
Kiyoto Mori
Biomedical Engineering for Cancer
Ohoku University
Japan
E-mail: kiyoto@mori.com.jp

Received:25-Aug-2023, Manuscript No. AAMOR-23-112351; Editor assigned:28-Aug-2023, PreQC No. AAMOR-23-112351 (PQ); Reviewed:11-Sep-2023, QC No. AAMOR-23-112351; Revised:16-Sep-2023, Manuscript No. AAMOR-23-112351 (R); Published:23-Sep-2023, DOI:10.35841/ aamor-7.5.193

Citation: Mori K. Making individualized treatment plans for multi-drug chemotherapy. J Mol Oncol Res. 2023;7(5):193

Visit for more related articles at Journal of Molecular Oncology Research

Introduction

Chemotherapy, also known as "chemo," is a crucial component in the fight against cancer. Powerful medications are used in this medical procedure to fight malignant cells and stop their growth or spread throughout the body. The key tools used in this valiant battle against one of the most difficult and persistent diseases known to humanity are chemotherapy medications [1].

Numerous individuals who have been diagnosed with cancer of all forms and stages are given hope by these medications, which are the cornerstone of cancer treatment procedures. Chemotherapy medication use has changed dramatically over time as a result of advancements in drug discovery, administration methods, and our understanding of how chemotherapy drugs affect the human body. Many cancer patients now have better outcomes and higher survival rates as a result of this advancement [2].

Chemotherapy has shown to be a potent tool in the never-ending fight against cancer. However, not all malignancies are the same, and hence, not all cancer treatments should be the same. Individualized treatment plans have become an essential strategy to increase chemotherapy's efficacy while reducing side effects. When multi-drug chemotherapy is required, results can be greatly enhanced by customizing these regimens to each patient's particular needs [3].

There are many factors at play in the complicated and varied disease of cancer. What is effective for one patient might not be appropriate for another. This is especially true when it comes to multi-drug chemotherapy, which employs the simultaneous or sequential administration of a number of drugs to attack cancer cells from several angles. Although these regimens have a high potential for effectiveness, they also carry a higher risk of complications and adverse effects [4].

Even while multi-drug chemotherapy has shown some potential, not all patients react the same way to these treatments. The type and stage of the patient's cancer, their general health, and their genetic makeup can all have a substantial impact on how well they tolerate and respond to chemotherapy. This variation emphasizes the need for personalized treatment strategies that take into account a patient's particular circumstances [5].

Conclusion

Individualized treatment regimens for multi-drug chemotherapy are a significant achievement in the field of cancer treatment. Incorporating the individual characteristics of the patient and the cancer, this personalized approach leads to better outcomes and a higher quality of life for people battling this difficult illness. As knowledge of cancer biology and genetics grows, cancer care will increasingly be individualized. By adopting this strategy, oncologists are able to provide patients with the most beneficial and safest treatment alternatives, giving them hope and a way to recover in the fight against cancer.

References

  1. Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: A study of the european osteosarcoma intergroup. Lancet. 1997;350(9082):911-7.

    2. Indexed at, Google Scholar, Cross Ref

  2. Schwab AE, Churcher TS, Schwab AJ, et al. An analysis of the population genetics of potential multi-drug resistance in wuchereria bancrofti due to combination chemotherapy. Parasi. 2007;134(7):1025-40.

    3. Indexed at, Google Scholar, Cross Ref

  3. Azharuddin M, Roberg K, Dhara AK, et al. Dissecting multi drug resistance in head and neck cancer cells using multicellular tumor spheroids. Sci Rep. 2019;9(1):20066.

    4. Indexed at, Google Scholar, Cross Ref

  4. Magombedze G, Garira W, Mwenje E, et al. Optimal control for HIV-1 multi-drug therapy. nt J Math Comput Sci. 2011;88(2):314-40.

    5. Google Scholar

  5. Ledzewicz U, Schättler H, Gahrooi MR, et al. On the MTD paradigm and optimal control for multi-drug cancer chemotherapy. Math Bio Sci. Eng. 2013;10(3):803-19.

    6. Indexed at, Google Scholar, Cross Ref

Get the App